FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person [*] Celano Michael		2. Issuer Name and Ticker or Trading Symbol Larimar Therapeutics, Inc. [LRMR]		all applicable)	10% Owner					
(Last) (First) C/O LARIMAR THERAPEUTI	(Middle) JTICS, INC.	3. Date of Earliest Transaction (Month/Day/Year) 05/17/2023	ar) Director 10% Owner X Officer (give title below) Other (specify below) //Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person ndication as made pursuant to a contract, instruction or written plan that is intended to	X	below)					
THREE BALA PLAZA EAST, SUITE 506		4. If Amendment, Date of Original Filed (Month/Day/Year)								
PA	19004			Form filed by More than One Reporting						
		Rule 10b5-1(c) Transaction Indication								
(State)	(Zip)									
	hael (First) R THERAPEU A PLAZA EAS	hael (First) (Middle) R THERAPEUTICS, INC. A PLAZA EAST, SUITE 506 PA 19004	hael Larimar Therapeutics, Inc. [LRMR] (First) (Middle) R THERAPEUTICS, INC. 3. Date of Earliest Transaction (Month/Day/Year) 05/17/2023 4. If Amendment, Date of Original Filed (Month/Day/Year) PA 19004 (State) (Zip)	hael Larimar Therapeutics, Inc. [LRMR] (Check (First) (Middle) 3. Date of Earliest Transaction (Month/Day/Year) X A PLAZA EAST, SUITE 506 4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Indiv PA 19004 Rule 10b5-1(c) Transaction Indication (State) (Zip) Check this box to indicate that a transaction was made pursuant to a cont	hael Larimar Therapeutics, Inc. [LRMR] (Check all applicable) (First) (Middle) R THERAPEUTICS, INC. 3. Date of Earliest Transaction (Month/Day/Year) Chief Financial VPLAZA EAST, SUITE 506 4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filin PA 19004 Rule 10b5-1(c) Transaction Indication Rule 10b5-1(c) Transaction Indication					

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Transaction Code (Instr.		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		
Common Stock	05/17/2023		Р		5,000	A	\$3.7263 ⁽¹⁾	112,746	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$3.71 to \$3.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.

/s/ Jennifer Johansson,

Attorney-in-fact

05/18/2023

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

OMB APPROVAL

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

obligations may continue. See Instruction 1(b).